Outlook Therapeutics, Inc. (OTLK) |
| 0.5614 -0.013 (-2.23%) 01-13 16:00 |
| Open: | 0.575 |
| High: | 0.5771 |
| Low: | 0.5455 |
| Volume: | 3,257,899 |
| Market Cap: | 25(M) |
| PE Ratio: | -0.31 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.54 |
| Resistance 1: | 1.76 |
| Pivot price: | 1.16 |
| Support 1: | 0.50 |
| Support 2: | 0.42 |
| 52w High: | 3.39 |
| 52w Low: | 0.501 |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Financials
| EPS | -66940000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 18.00 |
| Return on Assets (ttm) | 863.9 |
| Return on Equity (ttm) | -176.8 |
Company news
Thu, 01 Jan 2026
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form - Yahoo Finance
Wed, 31 Dec 2025
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewswire
Wed, 31 Dec 2025
OTLK Stock Flying High: What Fuels the Surge? - StocksToTrade
Wed, 31 Dec 2025
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA - Ophthalmology Times
Wed, 31 Dec 2025
US FDA declines to approve Outlook's eye disease drug for second time in 2025 - Reuters
Sun, 28 Dec 2025
Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again (NASDAQ:OTLK) - Seeking Alpha
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
